Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency

AOP acknowledges funding from the Dutch Medical Research Council (ZonMw), grant no. 09120011910035. CVL and OR acknowledge funding from the Belgian National Fund for Scientific Research (F.R.S-FNRS, Belgium); the French INSERM agency “ANRS/Maladies infectieuses émergentes”; the “Télévie” program of the F.R.S.-FNRS; ViiV Healthcare; the “Fondation Roi Baudouin”; the Internationale Brachet Stiftung (IBS); the Walloon Region (“Fonds de Maturation”); The “Amis des Instituts Pasteur à Bruxelles”, asbl.; the University of Brussels (ULB - Action de Recherche Concertée (ARC) grant); the NEAT (European AIDS Treatment Network) program; the University of Brussels (Action de Recherche Concertée ULB grant); the Marie Skłodowska-Curie COFUND action; and the European Union’s Horizon 2020 research and innovation program under grant agreement No 691119-EU4HIVCURE-H2020-MSCA-RISE-2015. CVL is “Directrice de Recherches” of the F.R.S-FNRS. The laboratory of CVL is part of the ULB-Cancer Research Centre (U-CRC) (Faculty of Medicine, ULB). AKP acknowledges funding from the National Science Centre, Poland (Sonata Bis Grant UMO2018/30/E/NZ1/00874).